AOCS has supported many research project both nationally and internationally. To June 2018, AOCS-enabled research has resulted in 282 peer-reviewed publications. Those from 2013 onwards are listed below, or the complete list is available here.
2020 Publications |
||
| Author | Title of Paper | PubMed Link |
| Gorringe KL et al | Therapeutic options for mucinous ovarian carcinoma | Click to view |
2019 Publications |
||
| Author | Title of Paper | PubMed Link |
| Cheasley D et al | The molecular origin and taxonomy of mucinous ovarian carcinoma | Click to view |
| Christie EL et al | Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer | Click to view |
| Harris HR et al | Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study | Click to view |
| Kondrashova O et al | Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study | Click to view |
| Lawrenson K et al | Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women | Click to view |
| Mavaddat N et al | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American journal of human genetics | Click to view |
| Minlikeeva AN et al | Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes Control | Click to view |
| Nagle CM et al | The association between the inflammatory potential of diet and risk of developing, and survival following, a diagnosis of ovarian cancer | Click to view |
| Takenaka M et al | Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype | Click to view |
2018 Publications |
||
| Author | Title of Paper | PubMed Link |
| Aziz D et al | 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes | Click to view |
| Babic A et al | Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium | Click to view |
| Block MS et al | MyD88 and TRL4 Expression in Epithelial Ovarian Cancer | Click to view |
| Colombo M et al | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity | Click to view |
| Dixon-Suen SC et al | Adult height is associated with increased risk of ovarian cancer: a Medelian randomisation study | Click to view |
| Dobrovic A | White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk: A Perspective | Click to view |
| Garsed DW et al | Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer | Click to view |
| Harris HR et al | Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium | Click to view |
| Heinzelmann-Schwarz V et al | Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients | Click to view |
| Hillman RT et al | Genomic Rearrangement Signatures and Clinical Outcomes in High Grade Serous Ovarian Cancer | Click to view |
| Kelemen LE et al | rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology | Click to view |
| Kondrashova O et al | Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma | Click to view |
| Lindemann K et al | Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance | Click to view |
| Moujaber T et al | BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition | |
| O’Donnell T et al | Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer | Click to view |
| Peres LC et al | Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies | Click to view |
| Rambau PF et al | Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study | Click to view |
| Ring BZ et al | Transducin-Like Enhancer of Split 3 (TLE3) expression is associated with taxane sensitivity in non-serous ovarian carcinoma in a three-cohort study | Click to view |
| Ugai T et al | Ovarian cancer risk. ALDH2 polymorphism and alcohol drinking: Asian data from the ovarian cancer Association Consortium | Click to view |
2017 Publications |
||
| Author | Title of Paper | PubMed Link |
| Babic A et al | Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium | Click to view |
| Day FR et al | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. | Click to view |
| Dixon SC et al | Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium | Click to view |
| Etemadmoghadam D et al | EIF1AX and NRAS Mutations Co-occur and Co-operate in Low-Grade Serous Ovarian Carcinomas | Click to view |
| Fagerholm R et al | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer | Click to view |
| Glubb DM et al | Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci | Click to view |
| Goode, Ellen et al | Dose-Response Relationship of CD8+ Tumor Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer | Click to view |
| Guo Q et al | Body mass index and breast cancer survival: a Mendelian randomization analysis | Click to view |
| Jiao X et al | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1 | Click to view |
| Kondrashova O et al | Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma | Click to view |
| Kondrashova O et al | Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma | Click to view |
| Liu G et al | Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence | Click to view |
| Michailidou K et al | Association analysis identifies 65 new breast cancer risk loci | Click to view |
| Milne RL et al | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | Click to view |
| Minlikeeva AN et al | History of Comorbidities and Survival of Ovarian Cancer Patients: Results from the Ovarian Cancer Association Consortium | Click to view |
| Minlikeeva AN et al | History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium | Click to view |
| Minlikeeva AN et al | History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report | Click to view |
| Phelan CM et al | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer | Click to view |
| Playdon MC et al | Pre-diagnosis diet and survival after a diagnosis of ovarian cancer | Click to view |
| Praestegaard C et al | Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies | Click to view |
| Rasmussen CB et al | Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled analysis of 13 Case-Control Studies | Click to view |
| Reid BM et al | Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci | Click to view |
| Ryland GL et al | Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors | Click to view |
| Shimelis H et al | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer | Click to view |
| Sucheston-Campbell LE et al | No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival | Click to view |
| Yang WL et al | Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer | Click to view |
2016 Publications |
||
| Author | Title of Paper | PubMed Link |
| Alsop K et al | A community-based model of rapid autopsy in end-stage cancer patients | Click to view |
| Bolton KL et al | Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer | Click to view |
| Cannioto R et al | Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium | Click to view |
| Cannioto R et al | Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium | Click to view |
| Cheng TH et al | Five endometrial cancer risk loci identified through genome-wide association analysis | Click to view |
| Cuellar-Partida G et al | Assessing the genetic architecture of epithelial ovarian cancer histological subtypes | Click to view |
| Dickson KA et al | The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer | Click to view |
| Dixon SC et al | Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study | Click to view |
| Easton DF et al | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing | Click to view |
| French JD et al | Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer | Click to view |
| Gao B et al | Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome | Click to view |
| Ghoussaini M et al | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation | Click to view |
| Hamdi Y et al | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21 | Click to view |
| Hamprass SS et al | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer | Click to view |
| Horne HN et al | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus | Click to view |
| Jim HS et al | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC) | Click to view |
| Kar SP et al | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types | Click to view |
| Lawrenson K et al | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus | Click to view |
| Lei J et al | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium | Click to view |
| Mercieca-Bebber RL et al | Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time | Click to view |
| Ong JS et al | Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study | Click to view |
| Painter JN et al | Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer | Click to view |
| Pelttari LM et al | RAD51B in Familial Breast Cancer | Click to view |
| Permuth JB et al | Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk | Click to view |
| Permuth JB et al | Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration | Click to view |
| Pharoah PD et al | PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations | Click to view |
| Praestegaard C et al | The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer:A pooled analysis of 18 case-control studies | Click to view |
| Price MA et al | Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making? | Click to view |
| Sinha D et al | Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients | Click to view |
| Southey MC et al | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS | Click to view |
| Thompson DJ et al | CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer | Click to view |
| Usset JL et al | Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors | Click to view |
| Winham SJ et al | Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer | Click to view |
| Wyszynski A et al | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression | Click to view |
| Zeng C et al | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus | Click to view |
2015 Publications |
||
| Author | Title of Paper | PubMed Link |
| Amankwah EK et al | Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk | Click to view |
| Candido-dos-Reis FJ et al | Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer | Click to view |
| Carvajal-Carmona LG et al | Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk | Click to view |
| Chornokur G et al | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk | Click to view |
| Coetzee SG et al | Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci | Click to view |
| Crook A et al | Connecting patients, researchers and clinical genetics services: the experiences of participants in the Australian Ovarian Cancer Study (AOCS) | Click to view |
| Darabi H et al | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression | Click to view |
| Day FR et al | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair | Click to view |
| Hernandez L et al | A dual role for Caspase8 and NF-?B interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival | Click to view |
| Hunter SM et al | Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes | Click to view |
| Jim HS et al | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC) | Click to view |
| Johnatty SE et al | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium | Click to view |
| Kabish M etal | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER negative breast cancer | Click to view |
| Kar SP et al | Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk | Click to view |
| Keleman LE et al | Genome-wide significant risk associations for mucinous ovarian carcinoma | Click to view |
| Kondrashova O et al | High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq | Click to view |
| Kuchenbaecker KB et al | Identification of six new susceptibility loci for invasive epithelial ovarian cancer | Click to view |
| Lawrenson K et al | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer | Click to view |
| Lawrenson K et al | Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer | Click to view |
| Lee AW et al | Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study | Click to view |
| Leong HS et al | Efficient molecular subtype classification of high-grade serous ovarian cancer
|
Click to view |
| Lin WY et al | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk | Click to view |
| Lu Y et al | Shared genetics underlying epidemiological association between endometriosis and ovarian cancer | Click to view |
| Meeks et al | BRAC2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate and Ovarian Cancers | Click to view |
| Michailidou K et al | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer | Click to view |
| Nagle CM et al | Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival | Click to view |
| Nagle CM et al | Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium | Click to view |
| OCAC et al | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer | Click to view |
| O’Mara TA et al | Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer | Click to view |
| Orr N et al | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 | Click to view |
| Painter JN et al | Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk | Click to view |
| Patch AM et al | Whole-genome characterization of chemoresistant ovarian cancer | Click to view |
| Patch AM et al | Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer | Click to view |
| Ramus SJ et al | Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer | Click to view |
| Rudolph A et al | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors | Click to view |
| Ryland GL et al | Loss of heterozygosity: what is it good for? | Click to view |
| Ryland GL et al | Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors | Click to view |
| Sobral-Leite M et al | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis | Click to view |
| Song H et al | Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population | Click to view |
| Webb PM et al | Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer | Click to view |
| Zhang B et al | Height and Breast Cancer Risk: Evidence from Prospective Studies and Mendelian Randomization | Click to view |
2014 Publications |
||
| Author | Title of Paper | PubMed Link |
| Agarawal D et al | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium | Click to view |
| Au-Yeung G et al | Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS) | Click to view |
| Beesley VL et al | Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: A prospective analysis | Click to view |
| Block MS et al | Variation in NF-?B signaling pathways and survival in invasive epithelial ovarian cancer | Click to view |
| Butow, PN et al | Caring for women with ovarian cancer in the last year of life: a longitudinal study of caregiver quality of life, distress and unmet needs | Click to view |
| Charbonneau B et al | Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome | Click to view |
| Charbonneau B et al | Risk of ovarian cancer and the NF-?B pathway: genetic association with IL1A and TNFSF10 | Click to view |
| Dixon SC et al | Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival | Click to view |
| Emmanuel C et al | Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver | Click to view |
| Gao B et al | Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer | Click to view |
| Ghoussaini M et al | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation | Click to view |
| Hedditch EL et al | ABCA transporter gene expression and poor outcome in epithelial ovarian cancer | Click to view |
| Johnson N et al | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study | Click to view |
| Kelemen LE et al | Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk | Click to view |
| Khan S et al | MicroRNA related polymorphisms and breast cancer risk | Click to view |
| Köbel M et al | Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study | Click to view |
| Milne RL et al | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. | Click to view |
| Milne RL et al | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. | Click to view |
| Neill As et al | Dietary phyto-oestrogens and the risk of ovarian and endometrial cancers: findings from two Australian case-control studies | Click to view |
| Perry JR et al | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. | Click to view |
| Purrington KS et al | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade | Click to view |
| Topp MD et al | Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts | Click to view |
| Trabert B et al | Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium | Click to view |
2013 Publications |
||
| Author | Title of Paper | PubMed Link |
| Barnes DR et al | Estimating single nucleotide polymorphism associations using pedigree data: applications to breast cancer. | Click to view |
| Baumbusch LO et al | High levels of genomic aberrations in serous ovarian cancers are associated with better survival | Click to view |
| Beesley VL et al | Changes in supportive care needs after first-line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needs. | Click to view |
| Bojesen SE et al | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. | Click to view |
| Dixon SC et al | Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival | Click to view |
| Earp MA et al | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA | Click to view |
| Etemadmoghadam D et al | Synthetic lethality between CCNE1 amplification and loss of BRCA1 | Click to view |
| Faber MT et al | Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies | Click to view |
| George J et al | Non-equivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations | Click to view |
| Hallowell N et al | The responses of research participants and their next of kin to receiving feedback of genetic test results following participation in the Australian Ovarian Cancer Study | Click to view |
| Johnatty SE at al | ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas | Click to view |
| Jordan S et al | Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer–a population-based study | Click to view |
| Kelemen LE et al | Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium | Click to view |
| Kondalsamy-Chennakesavan S et al | Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient’s age | Click to view |
| Meyer KB et al | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1 | Click to view |
| Michailidou K et al | Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Click to view |
| Mikeska T et al | No evidence for PALB2 methylation in high-grade serous ovarian cancer | Click to view |
| Nagle CM et al | Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis. | Click to view |
| Nickels S et al | Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors | Click to view |
| Olsen CM et al | Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium | Click to view |
| Pearce CL et al | Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. Cancer epidemiology, biomarkers & prevention | Click to view |
| Permuth-Wey J et al | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 | Click to view |
| Pharoah PD et al | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer | Click to view |
| Poole EM et al | Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness | Click to view |
| Price MA et al | Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: a prospective population-based study over the last year of life | Click to view |
| Rudolph A et al | Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study | Click to view |
| Ryland GL et al | RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary | Click to view |
| Shen H et al | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer | Click to view |
| Sieh W et al | Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies | Click to view |
| Terry KL et al | Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls | Click to view |
| White KL et al | Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome | Click to view |
Social Media